Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study.

Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, Elisabet Lidbrink, Nina Jebsen, Hans Hagberg, Karin Papworth, Oskar Hagberg, Clement Trovik, Henrik Bauer, Mikael Eriksson
{"title":"Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study.","authors":"Kirsten Sundby Hall,&nbsp;Øyvind S Bruland,&nbsp;Bodil Bjerkehagen,&nbsp;Elisabet Lidbrink,&nbsp;Nina Jebsen,&nbsp;Hans Hagberg,&nbsp;Karin Papworth,&nbsp;Oskar Hagberg,&nbsp;Clement Trovik,&nbsp;Henrik Bauer,&nbsp;Mikael Eriksson","doi":"10.1186/s13569-020-00145-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant chemotherapy. Herein we report the results of this group B.</p><p><strong>Methods: </strong>Twenty patients with high-grade, locally advanced and deep STS located in lower extremities (n = 12), upper extremities (5) or trunk wall (3) were included. The median age was 59 years and 14 patients were males. The treatment regimen consisted of 6 cycles of doxorubicin (60 mg/m<sup>2</sup>) and ifosfamide (6 g/m<sup>2</sup>), with three cycles given neoadjuvantly, and preoperative radiotherapy (1, 8 Gyx2/daily to 36 Gy) between cycles 2 and 3. After a repeated MRI surgery was then conducted, and the remaining 3 chemotherapy cycles were given postoperatively at 3 weeks intervals. Survival data, local control, toxicity of chemotherapy and postoperative complications are presented.</p><p><strong>Results: </strong>Median follow-up time for metastasis-free survival (MFS) was 2.8 years (range 0.3-10.4). The 5-year MFS was 49.5% (95% confidence interval [CI] 31.7-77.4). The median follow-up time was 5.4 years (range 0.3-10.4) for overall survival (OS). The 5-year OS was 64.0% (95% CI 45.8-89.4). The median tumour size was 13 cm, with undifferentiated pleomorphic sarcoma (n = 10) and synovial sarcoma (n = 6) diagnosed most frequently. All patients completed surgery. Resection margins were R0 in 19 patients and R1 in 1 patient. No patients had evidence of disease progression preoperatively. Three patients experienced a local recurrence, in 2 after lung metastases had already been diagnosed. Eleven patients (55%) had postoperative wound problems (temporary in 8 and persistent in 3).</p><p><strong>Conclusions: </strong>Preoperative chemotherapy and radiotherapy were associated with temporary wound-healing problems. Survival outcomes, local control and toxicities were deemed satisfactory when considering the locally advanced sarcoma disease status at primary diagnosis. Trial registration This study was registered at ClinicalTrials.gov Identifier NCT00790244 and with European Union Drug Regulating Authorities Clinical Trials No. EUDRACT 2007-001152-39.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"10 1","pages":"22"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-020-00145-5","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-020-00145-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Background: We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant chemotherapy. Herein we report the results of this group B.

Methods: Twenty patients with high-grade, locally advanced and deep STS located in lower extremities (n = 12), upper extremities (5) or trunk wall (3) were included. The median age was 59 years and 14 patients were males. The treatment regimen consisted of 6 cycles of doxorubicin (60 mg/m2) and ifosfamide (6 g/m2), with three cycles given neoadjuvantly, and preoperative radiotherapy (1, 8 Gyx2/daily to 36 Gy) between cycles 2 and 3. After a repeated MRI surgery was then conducted, and the remaining 3 chemotherapy cycles were given postoperatively at 3 weeks intervals. Survival data, local control, toxicity of chemotherapy and postoperative complications are presented.

Results: Median follow-up time for metastasis-free survival (MFS) was 2.8 years (range 0.3-10.4). The 5-year MFS was 49.5% (95% confidence interval [CI] 31.7-77.4). The median follow-up time was 5.4 years (range 0.3-10.4) for overall survival (OS). The 5-year OS was 64.0% (95% CI 45.8-89.4). The median tumour size was 13 cm, with undifferentiated pleomorphic sarcoma (n = 10) and synovial sarcoma (n = 6) diagnosed most frequently. All patients completed surgery. Resection margins were R0 in 19 patients and R1 in 1 patient. No patients had evidence of disease progression preoperatively. Three patients experienced a local recurrence, in 2 after lung metastases had already been diagnosed. Eleven patients (55%) had postoperative wound problems (temporary in 8 and persistent in 3).

Conclusions: Preoperative chemotherapy and radiotherapy were associated with temporary wound-healing problems. Survival outcomes, local control and toxicities were deemed satisfactory when considering the locally advanced sarcoma disease status at primary diagnosis. Trial registration This study was registered at ClinicalTrials.gov Identifier NCT00790244 and with European Union Drug Regulating Authorities Clinical Trials No. EUDRACT 2007-001152-39.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高危软组织肉瘤患者的术前加速放疗联合化疗:斯堪的纳维亚肉瘤组研究
背景:我们最近报道了一项斯堪的纳维亚肉瘤组辅助研究(SSG XX a组)的结果,该研究对四肢和躯干壁的局限性和可手术的高风险软组织肉瘤(STS)进行了研究。SSG XX, B组,由确定的局部晚期STS患者队列组成,被认为是局部内手术的高风险患者。这些患者术前接受加速放疗,同时接受新辅助和辅助化疗。方法:包括20例位于下肢(n = 12)、上肢(5)或躯干壁(3)的高级别、局部晚期和深度STS患者。中位年龄59岁,男性14例。治疗方案包括6个周期的阿霉素(60mg /m2)和异环磷酰胺(6g /m2),其中3个周期为新辅助治疗,在第2和第3周期之间进行术前放疗(1,8 Gyx2/日至36 Gy)。再次行MRI手术后,术后每隔3周给予其余3个化疗周期。报告了生存数据、局部控制、化疗毒性和术后并发症。结果:无转移生存期(MFS)的中位随访时间为2.8年(范围0.3-10.4)。5年MFS为49.5%(95%可信区间[CI] 31.7-77.4)。总生存期(OS)的中位随访时间为5.4年(范围0.3-10.4)。5年OS为64.0% (95% CI 45.8-89.4)。肿瘤中位大小为13 cm,以未分化多形性肉瘤(n = 10)和滑膜肉瘤(n = 6)诊断最多。所有患者均完成手术。切除边缘19例为R0, 1例为R1。术前患者无疾病进展迹象。3例患者局部复发,2例已确诊肺转移。11例(55%)患者术后出现伤口问题(8例为暂时性问题,3例为持续性问题)。结论:术前化疗和放疗与暂时性伤口愈合问题相关。在初次诊断时考虑局部晚期肉瘤疾病状态时,生存结果、局部控制和毒性被认为是令人满意的。本研究已在ClinicalTrials.gov注册,注册号NCT00790244,欧盟药物监管局临床试验号NCT00790244。EUDRACT 2007-001152-39。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍: Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
期刊最新文献
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response. The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma. Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report. Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1